Thermo Fisher Scientific reported second-quarter 2026 results with revenue of $11.99 billion and adjusted diluted EPS of $6.03. GAAP diluted EPS was $4.68 and net income attributable to the company was $1.736 billion for the quarter. Organic revenue growth was 5% year-over-year, with consolidated GAAP operating income of $2.087 billion.

Financial Highlights

  • Revenue: $11.99 billion for the three months ended June 27, 2026 (10% growth versus prior year).
  • GAAP operating income: $2.087 billion (GAAP operating margin 17.4%).
  • Net income attributable to Thermo Fisher Scientific: $1.736 billion.
  • GAAP diluted EPS: $4.68 for the quarter.
  • Adjusted diluted EPS (non-GAAP): $6.03; adjusted operating income: $2.735 billion (adjusted operating margin 22.8%).

Business Highlights

  • Organic revenue growth of 5% in the quarter (reported revenue growth 10% with 5% from acquisitions and 1% currency impact).
  • Launched new products including next‑generation Orbitrap mass spectrometers (Tribrid Apex and Excedion) and the Applied Biosystems PowerFlex thermal cycler to support multiomics, structural biology and PCR workflows.
  • Opened flagship U.S. Bioprocess Design Center in Plainville, Massachusetts to expand collaborative hubs for pharma and biotech customers.
  • Announced strategic collaboration with Precision Health Research, Singapore to support the PRECISE‑SG100K population health study leveraging integrated proteomics capabilities.
  • Continued capital deployment actions during the quarter, including the divestiture of the microbiology business and repurchases of $1.0 billion of company stock.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.